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pneumonia and meningoencephalitis among patients with
reduced cell mediated immunity. Among patients infected with
human immunodeﬁciency virus (HIV), most of the cases of
cryptococcosis occur with a CD4 cell count of <100 cells/mm3New Microbes and New Infections © 2014 The Authors. Published by El
This is an open access arti[1]. Diagnosis is based on blood or cerebrospinal ﬂuid (CSF)
cultures and on immunoassays often used to detect
C. neoformans surface capsular polysaccharide glucuronox-
ylomannan (GXM) shed during infection [2–5]. In HIV-infected
patients, sensitivity of cryptococcal antigen detection in CSF
approaches 99% [6]. Nevertheless, cryptococcosis with false-
negative antigen results has been reported [7–9].
In the present study, we report a case of cryptococcal
meningoencephalitis in an HIV-infected patient with initial
negative cryptococcal antigen detection. We reviewed cryp-
tococcal antigen assays at our institution over the last 25 years
and evaluated a new immunochromatographic detection assay
that exhibited a higher sensitivity.
In July 2013, a 29-year-old woman was seen at our
outpatient infectious diseases clinic for an HIV infection that
was diagnosed 4 months before in Cameroon. Antitubercu-
losis treatment for a likely pulmonary tuberculosis had been
started at HIV diagnosis. The patient complained about fever
and cough that had lasted for several weeks. At baseline
workup, CD4+ cell count was 140/mm3, and HIV virus load
was 1.2 × 106 copies/mL. A ﬁrst serum cryptococcal antigen
(July 2013) was negative using the Pastorex immunoaggluti-
nation assay (Bio-Rad, Marnes la Coquette, France) (Fig. 1). A
right lower lobe inﬁltrate was seen on chest x-ray. Bron-
choalveolar lavage was negative for Mycobacterium tuberculosis
(PCR, culture) and fungi (silver stain, culture). Co-
trimoxazole for Pneumocystis jirovecii pneumonia prophylaxis
was started (while waiting for the result of HIV genotypic
analysis to initiate antiretroviral therapy), and antituberculosis
treatment was pursued. Two weeks later, fever persisted and
the patient developed diffuse intense holocranial headache
that led to her admission to the emergency department. At
examination, her temperature was 38.2°C, and her vital signs
were normal. There was no neck stiffness, and the neurologic
examination was normal. Brain magnetic resonance imaging
showed a contrast-enhancing nodule about 6 mm of diameter
in the left posterior parietal lobe without edema or signs of
intracranial hypertension. CSF opening pressure was 7 cm
H2O, and CSF examination revealed 192 leucocytes/mm
3
(lymphocytes 88%), while protein level was 1775 mg/L, lactate
level was 2.8 mmol/L and CSF/blood glucose ratio was 0.4. No
microorganisms were observed on CSF staining. Bacterial and
mycobacterial cultures were negative. Cryptococcal antigen in
serum and CSF was negative (Fig. 1). Two days later, the CSF
culture became positive. Microscopic observation revealed
the presence of yeastlike organisms that we identiﬁed as
C. neoformans using MALDI-TOF (matrix-assisted laser
desorption-ionization time-of-ﬂight) analysis (Bruker Dal-
tonics, Leipzig, Germany) with a spectral score above 2New Microbe and New Infect 2015; 4: 1–4
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FIG. 1. Time course of the case study and
treatment. The buttom part of the ﬁgure
shows results of cryptococcal antigen titers
and cryptococcal culture. Cryptococcal
antigen titers were determined by immu-
noagglutination (Pastorex) and lateral ﬂow
assay (Immunomycologics Inc., IMMY).
Quantitative culture was achieved as fol-
lows: four drops of 100 μL, 50 μL, and
10 μL were deposited in duplicate on a
brain–heart infusion plate supplemented
with blood and incubated at 37°C with
CO2. Antifungal and antiretroviral treat-
ment is depicted in the upper part of the
ﬁgure. Antifungal treatment consisted of
liposomal amphotericin B (5 mg/kg) and
intravenous ﬂucytosine (25 mg/kg every
other day). After 2 weeks of combined
therapy, the patient was apyretic and
headache disappeared; lumbar puncture
revealed normal opening pressure and
decreased amount of protein (862 mg/L),
and CSF culture was sterile. Cryptococcal
antigen detection in the CSF became nega-
tive as well. Antifungal treatment was
switched to ﬂuconazole (400 mg once daily)
and antiretroviral treatment was initiated,
without relapse of cryptococcal meningitis.
2 New Microbes and New Infections, Volume 4 Number C, March 2015 NMNI[10–12]. The same day, a CSF was collected, which came
positive for GXM antigen (titer 1:4) using the Pastorex
immunoagglutination assay (Fig. 1). We initiated antifungal
therapy with liposomal amphotericin B 5 mg/kg iv once daily
and ﬂucytosine 25 mg/kg every 6 hours during the ﬁrst 2
weeks, followed by ﬂuconazole 400 mg by mouth once daily
according to current guidelines [13], with a good outcome.
Antiretroviral therapy with tenofovir, emtricitabine, ralte-
gravir, darunavir and ritonavir was started after 2 weeks of
antifungal therapy.
In our 1027-bed tertiary-care university hospital, we use the
immunoagglutination assay Pastorex Crypto Plus 61747 (Bio-
Rad), based on latex beads coated with anti-GXM mouth
monoclonal antibodies [14,15]. From 1996 to 2013, 1759
samples (sera and CSF) from patients with suspicion of
C. neoformans infection were analysed using this assay; among
them, 152 samples tested positive (Fig. 2). The present case is
the ﬁrst of meningitis with positive C. neoformans culture and
negative cryptococcal antigen agglutination in our hospital. A
negative agglutination due to a prozone effect that can occur inNew Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licehigh antigen titers has been excluded by serial dilution and by
retesting of the sample. We thus hypothesize that the negative
result is due to a low fungus load (10 C. neoformans cfu/mL at
quantitative culture of the initial sample), possibly explained by
partially preserved immunity (CD4 cells above 100/mm3).
Because sensitivity may vary among different commercial
immunoassays, we retrospectively tested the negative samples
of our patient with the recent lateral ﬂow assay (LFA) detection
system from Immunomycologics Inc. (IMMY) [6,16]. This
immunochromatographic Point-of-Care test is based on the
qualitative and semiquantitative detection of GXM in sera and
CSF. The experimental sensitivity of the IMMY-LFA system (C5
to C95 interval = 1.0−1.5 ng/mL) determined with puriﬁed
GXM is higher than the sensitivity of the Pastorex immunoag-
glutination system from Bio-Rad (detection limit 50 ng/mL)
[17]. To validate the LFA assay in our laboratory, we retro-
spectively tested 50 CSF and sera from the collection of our
hospital (30 positive and 20 negative samples) previously ana-
lysed with the Pastorex system. We found 100% agreement
between the two systems. Antigen titers measured for positiveEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 4, 1–4
nses/by-nc-nd/4.0/)
FIG. 2. Cryptococcus neoformans infection over 18 years. (A) Total number of cryptococcal antigen detection by immunoagglutination and number of
positive results in our hospital from 1996 to 2014. Results were obtained with the Bio-Rad assay Pastorex Crypto Plus 61747. (B) Evolution of
cryptococcal antigen titer among positive results: comparison between 1996–2004 and 2005–2013 (comparison by Mann-Whitney test). Antigen titer
for positive samples was determined by serial dilution according to the manufacturer’s procedure.
NMNI Opota et al. Cryptococcus neoformans meningitis 3samples were always higher with the IMMY-LFA system than
with the Pastorex assay (Fig. 3; Supplementary Table 1). The
samples from our patient that were negative with the Pastorex
immunoagglutination assay came positive with the IMMY-LFA
system (titer 1:20) (Fig. 1). This suggests a higher sensitivity
of the IMMY-LFA compared to immunoagglutination assays.
This is consistent with two recent large studies, performed on
421 sera from HIV patients in Colombia and 589 sera and 411
CSF in the United States, respectively [18,19]. The negative case
that we report in this article might be due to the low fungus
load of C. neoformans (10 cfu/mL), which might be close to the
detection limit (Fig. 1).
The incidence of cryptococcal meningitis has decreased
since the advent of effective antiretroviral therapy [20,21].FIG. 3. Evaluation of the lateral ﬂow assay
(LFA) detection system from Immunomy-
cologics Inc. (IMMY). A total of 50 samples
(30 positive and 20 negative) previously
analysed with the immunoagglutination assay
Pastorex Crypto Plus 61747 (Bio-Rad) were
retrospectively tested with the IMMY-LFA
(Supplementary Table 1). The 20 samples
that were negative with the Pastorex assay
also came negative with the LFA assay (data
not presented). In 9 cases, immunochro-
matography was performed but the titration
could not be done because the volume of
stored CSF was not sufﬁcient. Antigen titers
were always higher with the IMMY-LFA
system than with the Pastorex assay (com-
parison by Wilcoxon signed rank test).
New Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on b
This is an open access artiSimilarly, infections with high antigen titer are less likely to
occur. In our hospital, we observed decreasing antigen titer for
positive samples over the last 18 years (Fig. 2B), with a median
titer of 72 during 1996–2004 versus 20 during 2005–2013
(p 0.003, comparison by Mann-Whitney test). Although we did
not have comprehensive data on quantitative cultures, this
suggests infections with a lower fungus load. In this context,
cryptococcosis cases with negative antigen results are more
likely to occur. Other causes of false-negative antigen results
can be high antigen titers (>1:256) leading to a prozone reac-
tion [22,23] or the presence of immune complexes that pre-
vent the shedding of GXM antigen [24]; alternatively, low
antigen release could be associated with poorly encapsulated
strains [25–27].ehalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 4, 1–4
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
4 New Microbes and New Infections, Volume 4 Number C, March 2015 NMNIIn conclusion, negative antigen results do not permit the
exclusion of cryptococcal infection, especially in the setting of
low fungus load. Immunochromatography systems should be
preferred over immunoagglutination assay, as they are easier to
handle and more sensitive.Conﬂict of interestNone declared.AcknowledgementsWe are grateful to all of the technicians of the Diagnostic
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